港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

579.360

+1.4270.25%

漲家數：14

跌家數：17

平家數：3

市盈率：- -

高：598.497

開：578.227

低：573.488

收：577.933

成交量：1.15億

成交額：33.86億

市值：3,682.12億

流通市值：3,290.33億

資料載入中...

總覽新聞資訊

交易額最高9475萬美元！英硅智能上市不到3個月，宣佈第4筆國內AI製藥合作

每日经济新闻

歐康維視生物-B(01477)：建議委任莊蓓蓓為獨立非執行董事

歐康維視生物-B(01477)發布年度業績，淨虧損1.59億元按年減少40.8%

康方生物(09926)發布年度業績，收入按年增長43.9%至30.56億元

康諾亞-B(02162)發布年度業績股東應占虧損5.23億元按年擴大1.44%

藥明巨諾-B(02126)發布年度業績年內虧損5.55億元按年收窄5.98%

藥明巨諾-B：CAR-T療法Carteyva作為R/R LBCL二線治療的sNDA預計2026年獲NMPA批准

邁博藥業-B(02181)發布年度業績股東應占溢利5713.3萬元按年扭虧為盈

分化與突圍：國藥、華潤2025業績出爐醫藥流通集中度提升

21世纪经济报道

中國生物製藥淨利增長31.4%，創新藥成產業升級核心引擎

21世纪经济报道

心瑋醫療-B(06609)發布年度業績股東應占溢利8333.5萬元出血性卒中業務收入按年大幅增長223.2%

先瑞達醫療-B(06669)公布2025年業績淨利約1.19億元按年增長128%

基石藥業-B(02616)公布PD-1/VEGF/CTLA-4三特異性抗體CS2009的最新臨床進展及I/II期關鍵臨床數據

《藍籌》中生製藥(01177.HK)全年純利跌33% 基本溢利增31.4% 末期息5港仙

阿斯达克财经

華領醫藥-B(02552)委任歐陽麗妮為公司秘書

一品紅(300723.SZ)子公司創新藥APH03571片獲得臨床試驗註冊申請受理

榮昌生物(09995)出現大手賣出12.5萬股，成交價$88.6，涉資1.108千萬

阿斯达克财经

天聖製藥曾因年報虛假引發索賠，部分案件已遞交立案

「AI製藥」的晶泰控股扭虧虛與實

华尔街见闻

老百姓大藥房與信達生物深化戰略合作攜手共拓創新藥市場

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":579.3598,"timestamp":1774512495612,"preClose":577.93304,"halted":0,"volume":115336870,"delay":0,"changeRate":0.002469,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":1.426758,"latestTime":"03-26 16:00:00","open":578.2267,"high":598.49725,"low":573.4878,"amount":3386124743,"amplitude":0.043274,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":5.179109,"peRate":-60.041027,"turnoverRate":0.004143,"increases":13,"decrements":20,"flats":0,"marketCap":368211528480,"floatMarketCap":329033220336},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":598.49725,"amplitude":0.043274,"preClose":577.93304,"low":573.4878,"pbRate":"5.179109","latestPrice":579.3598,"volume":115336870,"delay":0,"open":578.2267,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":571.212,"twentyDayClose":537.703,"sixtyDayClose":574.89,"secType":"PLATE","market":"HK","turnoverRate":0.004143,"peRate":-60.041027,"marketCap":368211528480,"floatMarketCap":329033220336,"timestamp":1774512495612,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":17,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622867591","title":"交易額最高9475萬美元！英硅智能上市不到3個月，宣佈第4筆國內AI製藥合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2622867591","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622867591?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 00:31","pubTimestamp":1774542710,"startTime":"0","endTime":"0","summary":"中国AI（人工智能）制药领域迎来一笔新合作。3月26日，英硅智能（HK03696，股价50.30港元，市值287.92亿港元）公告称，在过去一年良好的合作关系基础上，公司与元羿生物已达成一项扩展的AI驱动研发合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686033797.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686033797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","01477","AGIX","AIPO","BK1574","CHAT"],"gpt_icon":0},{"id":"2622786408","title":"歐康維視生物-B(01477)：建議委任莊蓓蓓為獨立非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2622786408","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622786408?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 23:47","pubTimestamp":1774540074,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，胡定旭先生于服务超过五年后，将根据公司的公司章程细则于公司应届股东周年大会上退任。胡先生已告知董事会，彼决定不于股东周年大会上膺选连任，以投入更多时间处理其他事务。鉴于胡先生即将退任，于2026年3月26日，董事会议决将于股东周年大会上建议委任庄蓓蓓女士为独立非执行董事，以填补胡先生退任后的董事会空缺，自股东周年大会结束起生效，惟须待股东批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2622486429","title":"歐康維視生物-B(01477)發布年度業績，淨虧損1.59億元 按年減少40.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622486429","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622486429?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 23:45","pubTimestamp":1774539902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布截至2025年12月31日止年度业绩，该集团取得收益8.04亿元，同比增加92.75%;年内亏损1.59亿元，同比减少40.8%;每股亏损0.2元。公司进一步拓展院内市场，主要产品销量保持稳定增长。博优景 获NMPA批准上市，用于治疗成人新生血管(湿性)年龄相关性黄斑变性及糖尿病黄斑水肿，这标志着公司在眼底疾病领域又一重要产品的诞生。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2622610318","title":"康方生物(09926)發布年度業績，收入按年增長43.9%至30.56億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622610318","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622610318?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 23:14","pubTimestamp":1774538074,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布截至2025年12月31日止年度业绩，该集团取得收入人民币30.56亿元，同比增加43.9%;毛利24.04亿元，同比增加31.01%;研发开支15.75亿元，同比增加32.61%;年内亏损11.41亿元，每股亏损1.23元。作为全球领先的双特异性抗体公司，康方生物2025年继续在世界一流的研发方面取得显著投资进展，同时较2024年缩小了Non-IFRS年内EBITDA，从而提升了财务表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","LU1961090484.USD","LU0634319403.HKD","LU0417516738.SGD","LU2488822045.USD","LU0348767384.USD","LU2399975544.HKD","LU0417516571.SGD","LU2476274308.USD","BK1574","BK1161","LU1720050803.USD","LU0561508036.HKD","LU2778985437.USD","LU0348766576.USD","LU0348825331.USD","09926","LU1794554557.SGD","LU0348784397.USD","LU0348783233.USD","LU0348827113.USD","LU0348735423.USD","LU0540923850.HKD","LU0417516902.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":1},{"id":"2622868626","title":"康諾亞-B(02162)發布年度業績 股東應占虧損5.23億元 按年擴大1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868626?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 20:58","pubTimestamp":1774529912,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B(02162)发布截至2025年12月31日止年度业绩，该集团期内取得收入7.16亿元人民币，同比增加67%;母公司拥有人应占亏损5.23亿元，同比扩大1.44%;每股基本亏损1.91元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1587","BK1574","BK1583","02162"],"gpt_icon":0},{"id":"2622857005","title":"藥明巨諾-B(02126)發布年度業績 年內虧損5.55億元 按年收窄5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622857005","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622857005?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 20:29","pubTimestamp":1774528180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明巨诺-B(02126)发布截至2025年12月31日止年度业绩，该集团期内取得收入2.84亿元人民币，同比增加79.3%;年内亏损5.55亿元，同比收窄5.98%;每股基本亏损1.34元。该收入主要来自(i)集团目前处于商业化的产品倍诺达®的销售;及(ii)向Juno授予JW sLVV生产工艺及相关技术知识(以及专利)的非独家许可。产品收入由截至2024年12月31日止年度的人民币1.58亿元增加38.4%至截至2025年12月31日止年度的人民币2.19亿元。截至2025年12月31日止年度确认非独家许可收入人民币 6450万元，为报告期间的整体收入增长作出贡献。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02126","BK1574","BK1583"],"gpt_icon":0},{"id":"1170225455","title":"藥明巨諾-B：CAR-T療法Carteyva作為R/R LBCL二線治療的sNDA預計2026年獲NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1170225455","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170225455?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 20:25","pubTimestamp":1774527918,"startTime":"0","endTime":"0","summary":"药明巨诺-B（JW Therapeutics）宣布，其CAR-T细胞疗法Carteyva（relma-cel）作为复发或难治性大B细胞淋巴瘤（R/R LBCL）二线治疗的补充新药申请（sNDA），预计将于2026年获得中国国家药品监督管理局（NMPA）的批准。\n这一进展标志着Carteyva在拓展适应症方面取得重要突破。若获批，该疗法将为R/R LBCL患者提供新的治疗选择，进一步巩固药明巨诺在细胞治疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02126","BK1574","BK1583"],"gpt_icon":0},{"id":"2622854919","title":"邁博藥業-B(02181)發布年度業績 股東應占溢利5713.3萬元 按年扭虧為盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854919","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854919?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 19:38","pubTimestamp":1774525130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈博药业-B(02181)发布截至2025年12月31日止年度业绩，营业收入6.46亿元(人民币，下同)，同比增长150.2%;公司拥有人应占溢利5713.3万元，同比扭亏为盈;每股基本盈利0.01元。公告称，股东应占溢利扭亏为盈主要是由于公司毛利增加以及将未来一年可抵扣的所得税确认为递延所得税费用所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"迈博药业-B(02181)发布年度业绩 股东应占溢利5713.3万元 同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02181"],"gpt_icon":0},{"id":"2622854081","title":"分化與突圍：國藥、華潤2025業績出爐 醫藥流通集中度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854081","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854081?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 19:14","pubTimestamp":1774523640,"startTime":"0","endTime":"0","summary":"在医药行业政策深化与市场竞争加剧的双重背景下，国内两大医药流通巨头国药控股与华润医药相继披露2025年业绩报告。数据显示，两家企业呈现\"一稳一进\"的差异化发展态势：国药控股在营收微降1.60%的背景下实现利润正增长，华润医药则凭借全业务板块发力实现营收净利双位数增长，折射出头部企业在行业转型期的不同战略选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685743923.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685743923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","159938","09939","BK1515"],"gpt_icon":0},{"id":"2622854774","title":"中國生物製藥淨利增長31.4%，創新藥成產業升級核心引擎","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854774","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854774?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 19:12","pubTimestamp":1774523520,"startTime":"0","endTime":"0","summary":"3月26日，在医药行业整体处于深度调整与结构重构的关键节点，中国生物制药（01177.HK）发布了财报，2025年该公司实现营收和净利润双位数增长。财报显示，2025年公司全年实现营收318.3亿元，同比增长10.3%，经调整Non-HKFRS归母净利润45.4亿元，同比增长31.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685746631.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685746631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1521","BK1589","01177","HK0000165453.HKD","BK1574","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","06978","BK1515","159992","BK1191","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2622859250","title":"心瑋醫療-B(06609)發布年度業績 股東應占溢利8333.5萬元 出血性卒中業務收入按年大幅增長223.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622859250","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622859250?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 18:50","pubTimestamp":1774522247,"startTime":"0","endTime":"0","summary":"智通财经APP讯，心玮医疗-B 发布截至2025年12月31日止年度业绩，该集团取得收益4.08亿元，同比增长46.9%;毛利2.9亿元，同比增长59.3%;研发成本4076.1万元，同比减少30.8%;股东应占溢利8333.5万元，同比扭亏为盈;每股基本盈利2.21元。于2025财政年度，公司取得收益人民币4.083亿元，同比增长46.9%。集团取得股东应占净利润人民币8333.5万元，较上年度的股东应占净亏损约人民币1360万元实现重大扭亏为盈。基于前述原因，公司的出血性卒中业务收入在2025年同比增长223.2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06609","BK1100","BK1574","BK1587"],"gpt_icon":0},{"id":"2622285850","title":"先瑞達醫療-B(06669)公布2025年業績 淨利約1.19億元 按年增長128%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622285850","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622285850?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 17:09","pubTimestamp":1774516180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先瑞达医疗-B 公布2025年业绩，收益约6.45亿元，同比增长20.7%;毛利约4.76亿元，同比增长18.3%;年内溢利约1.19亿元，同比增长128%;每股基本盈利0.4元。2025年是产品获批的收获期，公司成熟的多元化研发技术组合的协同效应取得成果。于报告期间，公司共获得国家药监局及北京药监局对11款产品的注册批准，其中多项产品代表了公司的里程碑式发布。同时，公司继续扩大全球布局。公司的外周射频消融系统于2025年10月获得美国FDA的510认证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06669","BK1100","BK1574"],"gpt_icon":0},{"id":"2622858900","title":"基石藥業-B(02616)公布PD-1/VEGF/CTLA-4三特異性抗體CS2009的最新臨床進展及I/II期關鍵臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2622858900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622858900?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 17:09","pubTimestamp":1774516159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展。在肺癌中展现强劲疗效：CS2009单药针对肺癌的I/II期初步疗效资料积极。截至2026年3月中旬，I期研究已共入组113例晚期实体瘤患者，中位元随访期约为6个月;II期研究已共入组85例患者。在TME中，PD-1和 CTLA-4的双重阻断作用通过与VEGFA的交联显著增强。同时，CS2009可优先结合PD-1和CTLA-4双阳性的肿瘤浸润T细胞，并最大程度上弱化对外周T细胞中CTLA-4调节通路的干扰。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","BK4023","LU1169589451.USD","BK1574","BK1161","PD","02616"],"gpt_icon":0},{"id":"2622483063","title":"《藍籌》中生製藥(01177.HK)全年純利跌33% 基本溢利增31.4% 末期息5港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2622483063","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622483063?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:37","pubTimestamp":1774514220,"startTime":"0","endTime":"0","summary":"中国生物制药公布2025年度业绩，收入318.34亿人民币(下同)，按年升10.3%。股东应占溢利23.43亿元，按年跌33%；每股盈利13.02分。连同已派发中期股息每股5港仙，全年合共派发股息每股10港仙。过往派息公布日期派息事项派息内容2025/08/18中期业绩股息：港元 0.05002025/03/20末期业绩股息：港元 0.0400 2024/08/13中期业绩股息：港元 0.03002024/03/28末期业绩股息：港元 0.0300若撇除已终止经营业务、若干非现金项目及联营公司影响，基本溢利45.41亿元，按年升31.4%。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190118104802209_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190118104802209_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512865/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512865/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","HK0000165453.HKD","01477","BK1574","BK1515","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177","BK1191","IE00BZ08YT58.USD","BK1521"],"gpt_icon":0},{"id":"2622583727","title":"華領醫藥-B(02552)委任歐陽麗妮為公司秘書","url":"https://stock-news.laohu8.com/highlight/detail?id=2622583727","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622583727?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:34","pubTimestamp":1774514093,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华领医药-B(02552)发布公告，袁颕欣女士(袁女士)已辞任本公司公司秘书及不再担任根据香港联合交易所有限公司证券上市规则第 3.05条所规定的本公司授权代表，均自2026年3月26日起生效。在袁女士辞任后，董事会欣然宣布委任欧阳丽妮女士(欧阳女士)为本公司公司秘书及上市规则规定的第3.05条所规定授权代表，均自2026年3月26日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"2622547837","title":"一品紅(300723.SZ)子公司創新藥APH03571片獲得臨床試驗註冊申請受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2622547837","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622547837?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:20","pubTimestamp":1774513225,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03571片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。APH03571是公司研制的拟用于携带 FLT3(全称：FMS-like tyrosine kinase3，译为 FMS 样酪氨酸激酶 3)突变的复发性或难治性急性髓系白血病(acutemyelogenous leukemia，简称：AML)成人患者的治疗药品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1161","159992","BK0239","BK1574","300723"],"gpt_icon":0},{"id":"2622837509","title":"榮昌生物(09995)出現大手賣出12.5萬股，成交價$88.6，涉資1.108千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837509","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622837509?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:08","pubTimestamp":1774512480,"startTime":"0","endTime":"0","summary":"[大手成交]荣昌生物(09995)在下午04:08出现大手卖出，成交量为12.5万，成交价为港币$88.6，涉资1.108千万。至目前为止，股价跌3.328%，今日最高价为$96.65，而最低价为$86.8，总成交量为633.599万股，总成交金额港币$5.81亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603267149/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603267149/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","09995","BK0239","LU2488822045.USD","688331","LU1064130708.USD","LU1969619763.USD","BK1574","BK1583","LU2148510915.USD","LU2328871848.SGD","LU1064131003.USD"],"gpt_icon":0},{"id":"2622250834","title":"天聖製藥曾因年報虛假引發索賠，部分案件已遞交立案","url":"https://stock-news.laohu8.com/highlight/detail?id=2622250834","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622250834?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 15:33","pubTimestamp":1774510380,"startTime":"0","endTime":"0","summary":"　　上海沪紫律师事务所刘鹏律师团队近日递交了一批次案件至法院立案，目前还在征集受损股民中。2025年11月8日，天圣制药公告收到中国证监会重庆证监局出具的《行政处罚决定书》。作为业内资深证券维权律师，刘鹏律师精准把握案件核心，诉讼经验丰富，索赔策略高效，为投资者争取最大权益，维权实力行业领先。专业决定胜算，经验确保结果，首选刘鹏律师，让您的索赔更稳妥、更高效！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2026-03-26/doc-inhsicuw2818235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2622783996","title":"「AI製藥」的晶泰控股扭虧虛與實","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783996","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622783996?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 14:52","pubTimestamp":1774507932,"startTime":"0","endTime":"0","summary":"港股“AI制药明星企业”晶泰控股交出了上市以来的首份扭亏答卷。\n2025年，晶泰控股实现营业收入8....","market":"sg","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3768447","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3768447","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“AI制药”的晶泰控股扭亏虚与实","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","AIPO","AGIX","02228","BK1574","BK1141","BK1617","CHAT","BK1191"],"gpt_icon":0},{"id":"2622783622","title":"老百姓大藥房與信達生物深化戰略合作 攜手共拓創新藥市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783622","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622783622?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 14:24","pubTimestamp":1774506240,"startTime":"0","endTime":"0","summary":"本报讯受处方外流持续推进影响，对于部分进院难度较大的创新药，零售药房已成为实现商业化落地、提升患者可及性的重要渠道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685418646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0502904849.HKD","BK1161","BK1589","603883","LU2097828474.EUR","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828631.EUR","LU0455707207.USD","LU2097828557.USD","BK1583","HK0000165453.HKD","BK0209","159992","LU2242644610.SGD","01801","06978","BK1574","LU2097828714.EUR","LU2097828805.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":299,"code":"91000000","status":"200"}]}}